Healthcare / BiotechnologyASX
$0.02
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-26.1M · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$65M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-106.3%
↓Gross Margin
40.3%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1383.2%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.8M · net income $-86.4M · FCF $-79.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.8M | $5.8M | $601820.00 | $102934.00 | — |
| Net Income | $-86.4M | $-86.4M | $-13.9M | $-9.2M | $-13.2M |
| EBITDA | $-82.2M | $-82.2M | $-13.8M | $-9.0M | $-13.0M |
| EPS | -0.05 | -0.05 | -0.01 | -0.01 | -0.01 |
| Gross Margin | 40.3% | 40.3% | 100.0% | 100.0% | — |
| Operating Margin | -1499.7% | -1499.7% | -2568.8% | -12431.1% | — |
| Net Margin | -1500.6% | -1500.6% | -2304.6% | -8893.1% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | — | — | 0.02 |
| Current Ratio | 2.56 | 2.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-79.6M | $-79.6M | $-26.1M | $-19.1M | $-14.1M |
| Returns | |||||
| ROE | -106.3% | -106.3% | -12.8% | -39.9% | -161.6% |
| Valuation | |||||
| P/B | 0.54 | 0.54 | 4.70 | 6.54 | 8.38 |
| Growth & Yield | |||||
| Revenue Growth | 856.6% | 856.6% | 484.7% | — | — |
| EPS Growth | -408.7% | -408.7% | -16.5% | 41.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-92.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.05
Residual
-92.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.